GC Pharma/Biocon Eye Low Price Strategy As Biosimilar Insulin Glargine Approved In Korea
Executive Summary
GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.
You may also be interested in...
Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.
Orange Grove CEO: Korean Opportunities A Priority In Global Expansion
US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.